[[(1R,3R,5R,7R)-7-(2,4-dioxopyrimidin-1-yl)-3-hydroxy-2,6-dioxabicyclo[3.2.1]octan-5-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氧环庚烷
• 英文名称: [[(1R,3R,5R,7R)-7-(2,4-dioxopyrimidin-1-yl)-3-hydroxy-2,6-dioxabicyclo[3.2.1]octan-5-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
• 化学式: C₁₁H₁₇N₂O₁₅P₃
• 分子量: 510.18
• InChiKey: HKUXKHOFVNFKRY-PNHWDRBUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -5.2
• 重原子数：
  31
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  248
• 氢给体数：
  6
• 氢受体数：
  15

文献信息

• [EN] 2',4'-BRIDGED NUCLEOSIDES FOR HCV INFECTION<br/>[FR] NUCLÉOSIDES 2', 4'-PONTÉS POUR L'INFECTION PAR LE VHC
  申请人：IDENIX PHARMACEUTICALS INC

  公开号：WO2014066239A1

  公开（公告）日：2014-05-01

  Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2',4'-bridged nucleosides which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the 2',4'-bridged nucleosides are of Formula 3001:(I) (3001); or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, where PD, B, W, X, RA, RB, RC and RD are as described herein.